Category: General Cardiology

Conversion to and from dabigatran to other anticoagulants is depending on the creatinine clearance, longer period for washout is needed as clearance drops.

Difficulties in onset and maintenance of sleep as well as feeling of non restorative sleep were associated with increase in risk of myocardial infarction.

Rivaroxaban is an anticoagulant that acts by selective direct inhibition of factor Xa. It is the latest oral anticoagulant to be approved by US FDA, after dabigatran.

Abnormal heart rate recovery after exercise predicts mortality. Abnormal heart rate recovery after cardiac rehabilitation predicts higher mortality.

Tecarfarin is a vitamin K analogue which acts by inhibiting vitamin K epoxide reductase.

Apixaban is a direct factor Xa inhibitor. It has an oral bioavailability of about fifty percent.

Rivaroxaban is direct, specific, competitive factor Xa inhibitor and it has a half life of five to thirteen hours.

In patients with atherosclerotic cardiovascular disease and LDL levels below 70 mg/dl, there was no added benefit by giving niacin along simvastatin.

Vorapaxar to standard therapy did not reduce the primary composite end point, but increased risk of major bleeding including intracranial hemorrhage.

Dabigatran: Class I recommendation (level of evidence B) as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in AF